title: Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results.
authors.affiliation: Abteilung für Chirurgie, Gynäkologie, Chemotherapie und Pathologie, Universität Wien, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Jakesz
authors.forename: G
authors.initials: G
authors.lastname: Reiner
authors.forename: M
authors.initials: M
authors.lastname: Schemper
authors.forename: A
authors.initials: A
authors.lastname: Reiner
authors.forename: G
authors.initials: G
authors.lastname: Blijham
authors.forename: H
authors.initials: H
authors.lastname: Rainer
authors.forename: D
authors.initials: D
authors.lastname: Dittrich
authors.forename: J
authors.initials: J
authors.lastname: Spona
authors.forename: B
authors.initials: B
authors.lastname: Schutte
authors.forename: M
authors.initials: M
authors.lastname: Reynders
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008408:Mastectomy; D008593:Menopause; D008727:Methotrexate / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012307:Risk Factors; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001388:Aziridines; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C016866:azimexon; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate